Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 78 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV MelanomaTerminatedNCT02200562Phase 1
- Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs ObservationCompletedNCT02196961Phase 2
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
- A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02174172Phase 1
- Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ MesotheliomaCompletedNCT02141347Phase 1
- Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic SyndromeCompletedNCT02117219Phase 1
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2
- Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity MelanomaCompletedNCT02115243Phase 1
- T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate CancerCompletedNCT02113657Early Phase 1
- Treatment of Advanced Melanoma With MK-3475 and PeginterferonCompletedNCT02112032Phase 1
- Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases MelanomaCompletedNCT02094391Phase 2
- MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).CompletedNCT02088112Phase 1
- Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT02077959Phase 1
- A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.Active, not recruitingNCT02068196Phase 4
- CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)CompletedNCT02043665Phase 1
- Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC PatientsCompletedNCT02040064Phase 1
- Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral TherapyCompletedNCT02028403Phase 1
- Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical ProstatectomyCompletedNCT02020070Phase 2
- Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)CompletedNCT02014636Phase 1
- A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced MalignanciesCompletedNCT02013804Phase 1
- A Study of DKN-01 in Combination With Paclitaxel or PembrolizumabCompletedNCT02013154Phase 1
- Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerCompletedNCT01998126Phase 1
- Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01988896Phase 1
- Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma PatientsTerminatedNCT01988077Phase 2
- LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabCompletedNCT01986426Phase 1
- Anti PD1 Antibody in Diffuse Intrinsic Pontine GliomaStatus unknownNCT01952769Phase 1/2
- SRS (Stereotactic Radiosurgery) Plus IpilimumabTerminatedNCT01950195Phase 1
- Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01940809Phase 1
- A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid TumoursCompletedNCT01938612Phase 1
- Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck CancerCompletedNCT01935921Phase 1
- Study of the Drug Ipilimumab for Metastatic Merkel Cell CarcinomaWithdrawnNCT01913691Phase 2
- Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast CancerActive, not recruitingNCT01898117Phase 2
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT01896999Phase 1/2
- Sipuleucel-T and Ipilimumab for Advanced Prostate CancerCompletedNCT01832870Phase 1
- 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAINActive, not recruitingNCT01822652Phase 1
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerSuspendedNCT01810913Phase 2/3
- Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaCompletedNCT01767454Phase 1
- Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01757639Phase 1
- Ipilimumab and Lenalidomide in Advanced CancerCompletedNCT01750983Phase 1
- Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorCompletedNCT01750580Phase 1
- Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic MelanomaCompletedNCT01743157Phase 1/2
- Ipilimumab and Imatinib Mesylate in Advanced CancerCompletedNCT01738139Phase 1
- Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver MetastasesTerminatedNCT01730157Early Phase 1
- Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT01729806Phase 1
- Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical CancerCompletedNCT01711515Phase 1
- Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic MelanomaWithdrawnNCT01689870Phase 1/2
- Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT01688492Phase 1/2
- Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast CancerCompletedNCT01676753Phase 1
- Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV MelanomaActive, not recruitingNCT01676649Phase 2
- A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic MelanomaCompletedNCT01656642Phase 1
- The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant MesotheliomaStatus unknownNCT01655888Phase 2
- A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic MelanomaCompletedNCT01654692Phase 2
- A Clinical Study With Tremelimumab as Monotherapy in Malignant MesotheliomaStatus unknownNCT01649024Phase 2
- Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are MetastaticCompletedNCT01643278Phase 1
- Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid TumorsCompletedNCT01629758Phase 1
- Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for MelanomaCompletedNCT01608594Phase 1
- A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaTerminatedNCT01604889Phase 1/2
- Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable MelanomaStatus unknownNCT01565837Phase 2
- Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant MelanomaTerminatedNCT01557114Phase 1
- Ipilimumab and GMCSF Immunotherapy for Prostate CancerWithdrawnNCT01530984Phase 2
- Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast CancerCompletedNCT01502592Phase 1
- A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2CompletedNCT01480323Phase 2
- Phase 1 Biomarker Study of Anti-PDL-1 in Advanced MelanomaWithdrawnNCT01455103Phase 1
- Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic MalignancyWithdrawnNCT01452334Phase 1
- Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant CancerCompletedNCT01445379Phase 1
- Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic MelanomaCompletedNCT01435369Phase 2
- IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic MelanomaWithdrawnNCT01409187Phase 1/2
- IPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaTerminatedNCT01409174Phase 1
- An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid TumorsCompletedNCT01397929Phase 1/2
- CT-011 and p53 Genetic Vaccine for Advanced Solid TumorsWithdrawnNCT01386502Phase 1
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01375842Phase 1
- Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in MelanomaCompletedNCT01363206Phase 2
- THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced DiseaseCompletedNCT01355120Phase 2
- Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced CancerCompletedNCT01352884Phase 1
- Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer PatientsTerminatedNCT01334099Phase 1
- The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung CancerCompletedNCT01331525Phase 2
- Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1CompletedNCT01216696Phase 2
- Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaCompletedNCT01176474Phase 1
- Tremelimumab and CP-870,893 in Patients With Metastatic MelanomaCompletedNCT01103635Phase 1
- Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal MelanomaCompletedNCT01034787Phase 2
- Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT01008358Phase 2
- Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for MelanomaCompletedNCT00972933Early Phase 1
- Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular CarcinomaTerminatedNCT00966251Phase 1/2
- Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I InfectionTerminatedNCT00962936Phase 1/2
- Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX AloneCompletedNCT00890305Phase 2
- Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder CancerWithdrawnNCT00880854Phase 1
- Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT00871481Phase 1/2
- Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid LeukemiaWithdrawnNCT00732186Phase 1
- Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00729950Phase 1
- Multiple Ascending Dose (MDX1105-01)CompletedNCT00729664Phase 1
- CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLActive, not recruitingNCT00586391Phase 1
- A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced MelanomaTerminatedNCT00585000Phase 1
- Safety And Efficacy Study Of CP-675,206 In HIV-Infected PatientsWithdrawnNCT00488995Phase 2
- Study to Compare Two Formulations of CP-675,206 Monoclonal AntibodyCompletedNCT00431275Phase 1
- Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical ResectionCompletedNCT00362713Phase 1
- Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV MelanomaWithdrawnNCT00357461Phase 2
- Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After TreatmentCompletedNCT00313794Phase 2
- Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00312975Phase 2
- Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289640Phase 2